精细的CYP2B6-模板系统用于研究其连接物代谢
Yasushi Yamazoe1, Kouichi Yoshinari2
1Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-Aoba, Aoba-ku, Sendai, 980-8578, Japan; Division of Risk Assessment, National Institute of Health Sciences, Tonomachi 3-25-26, Kawasaki-ku, Kawasaki 210-9501, Japan.
Drug metabolism and pharmacokinetics
|January 10, 2025
概括
这项研究完善了预测人类CYP2B6中介药物代谢的模板系统,提高了各种化学配体的准确性. 改进的系统为药物代谢途径提供了更可靠的估计和洞察.
科学领域:
- 药理动力学和药物新陈代谢
- 计算化学和分子建模
背景情况:
- 模板系统以前预测了人类CYP2B6中介反应.
- 细胞染色体P450酶 (CYPs) 对于药物代谢至关重要.
研究的目的:
- 改进模板系统,以更准确地预测人类CYP2B6介导反应.
- 纳入新的概念,如允许宽度,触发残留,残留启动的连接体运动和双分子结合.
主要方法:
- 通过新的机械概念来完善现有的模板系统.
- 精制系统的应用,以分析360种反应,涉及261种不同的化学物质作为CYP2B6配体.
- 人类CYP2B6和老鼠CYP2B1.6之间的基质特异性的比较.
主要成果:
- 这种精细的系统准确地预测了CYP2B6配体的基质状态,区域选择性,立体选择性和抑制.
- 之前研究的所有化学物质都成功地重新评估了.
- 人类CYP2B6和大鼠CYP2B1之间的"架子"残留物大小的差异被确定为明显的催化活性的潜在原因.
结论:
- 精细的CYP2B6-模板系统为各种配体提供了更可靠的人类CYP催化估计.
- 该系统提供解密信息,以帮助理解和预测药物代谢.
相关概念视频
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Drug Metabolism: Phase I Reactions
3.0K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.0K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
26


